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Background: Many strains of community-acquired methicillin-resistant Staphylococcus 
aureus have a pore-forming leukotoxin, referred to as Panton-Valentine leukocidin 
(PVL), which can cause severe necrotizing pneumonia. Linezolid (LZD) is a new 
antibacterial agent that has potent antibacterial activity against MRSA.  
Methods: We used a mouse model of hematogenous pulmonary infection to compare 
the efficacies of LZD and vancomycin (VCM) against pulmonary infection caused by 
PVL-positive S. aureus.  
Results: After antibiotics were administrated for 3 days, the numbers of viable bacteria 
in the control, VCM, and LZD groups were 6.77±0.14, 5.29±0.27, and 4.25±0.33 log 
cfu/lung (mean±SEM), respectively. LZD significantly decreased the number of viable 
bacteria in the lungs as compared with the control group and the VCM group (p<0.05). 
The survival rate at day 7 post-inoculation was higher in the LZD group (100%) than in 
the VCM group (50%) or control group (0%). Histopathological examination and 
cytokine analysis also showed beneficial efficacy of LZD in comparison with VCM. 
Conclusion: LZD significantly reduced bacterial numbers and inflammation in a mouse 
model of PVL-positive S. aureus hematogenous infection and improved the survival 





Community-acquired MRSA infection has been increasing worldwide1. The 
many strains of community-acquired MRSA have a phage harboring the 
Panton-Valentine leukocidin (PVL) genes.2-4 PVL is a pore-forming leukotoxin,5,6 and 
PVL-positive S. aureus can cause primary skin and soft-tissue infections,7 as well as 
severe necrotizing pneumonia in young immunocompetent patients.6,7 The mortality rate 
is 75%,4 and autopsy reveals extensive necrotic and hemorrhagic lesions of the trachea, 
bronchi, alveolar septa, and parenchyma. Thus, new treatment strategies are needed for 
PVL-positive S. aureus. 
Linezolid (LZD) has potent antibacterial activity against Gram-positive cocci, 
vancomycin-resistant enterococci, and MRSA. LZD was reported to be more effective 
than VCM in achieving microbiological eradication for the treatment of MRSA 
infections.9 
We established a mouse model of pulmonary infection with S. aureus by 
intravenous injection of bacteria enmeshed in agar beads.10-12 The aim of the present 
study was to compare the activity and efficacy of LZD and VCM against PVL-positive 
S. aureus hematogenous pulmonary infection in a model mouse.  
 
Materials and Methods 
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Bacterial strains and culture conditions 
PVL-positive S. aureus was kindly provided by Prof. T. Yamamoto (Niigata University, 
Niigata, Japan). This strain was classified as staphylococcal cassette chromosome mec 
(SCCmec ) type IV 6. The bacteria were stored at -80°C in Microbank (Pro-Lab 
Diagnostics, Ontario, Canada) until use. Bacteria ware grown at 37°C on Mueller 
Hinton II Agar (Becton Dickinson and Company, Sparks, MD, USA) or in brain-heart 
infusion (BHI) broth (BBL Microbiology System, Cockeysville, MD, USA). 
 
Antibiotics 
LZD (Pfizer Japan Inc., Tokyo, Japan) and VCM (Shionogi Pharmaceutical Co., Osaka, 
Japan) were dissolved in sterile water immediately before use. 
 
Determination of minimum inhibitory concentrations 
The minimum inhibitory concentration (MIC) of each agent was determined by the 
microplate dilution technique. Mueller-Hinton II medium (Becton Dickinson and 
Company) and an inoculum size of 5 ×105 cfu/ml was used. MIC was defined as the 
lowest concentration of the test agent that inhibited visible growth of bacteria after 18 





Six-week-old, male, ddY, specific pathogen-free mice were purchased from Shizuoka 
Agricultural Cooperative Association Laboratory Animals (Shizuoka, Japan). All 
animals were housed in a pathogen-free environment and received sterile food and 
water in the Laboratory Animal Center for Nagasaki University Graduate School of 
Biomedical Sciences. The experimental protocol was approved by the Ethics Review 
Committee for Animal Experimentation at Nagasaki University. 
 
Inoculum 
Inoculation was performed as previously described.10-12 Briefly, PVL-positive S. aureus 
was cultured overnight on Mueller Hinton II agar plates at 37°C. Bacteria were 
suspended in endotoxin-free sterile saline and harvested by centrifugation (3,000 rpm, 
4°C, 10 min). Organisms were resuspended in cold sterile saline and diluted to between 
2 × 1010 and 4 × 1010 cfu/ml, or 2 × 1011 and 4 × 1011 cfu/ml, as estimated by 
turbidimetry. The suspension was warmed to 42°C, and 10 ml of the suspension was 
then mixed with 10 ml of 4% (wt/vol) molten noble agar (Difco Laboratories, Detroit, 
MI, USA) at 42°C. The agar-bacterium suspension (1.0 ml) was placed into a 1.0-ml 
syringe, and the suspension was rapidly injected via a 26-gauge needle into 49 ml of 
rapidly stirred ice-cooled sterile saline. This procedure resulted in solidification of the 
6 
 
agar droplets into beads of approximately 200 m in diameter. The final concentration 
of agar was 0.04% (wt/vol), and the final number of bacteria was 2 × 108 to 4 × 108 
cfu/ml for cytokine, bacteriological, and histopathological studies or 2 × 109 to 4 × 109 
cfu/ml for survival studies. 
 
Animal model of hematogenous pneumonia 
A total of 0.25 ml of the suspension containing agar beads with bacteria was injected 
into the tail vein of each mouse (10 ml/kg of body weight). The method used for 
inducing infection has been described in detail elsewhere.10-12 Treatment commenced a 
day after inoculation by intraperitoneal administration. Animals were allocated into 3 
groups: LZD (100 mg/kg/dose), VCM (100 mg/kg/dose) or control. Each drug was 
administered twice daily for 1 day or 3 days for bacteriological study (n = 10 in each 
group), 3 days for histopathological and cytokine studies (n = 10 in each group), or 7 
days for survival studies (n = 6 in each group). 
 
Bacteriological, histopathological and survival examinations 
Mice were sacrificed by cervical dislocation 12h after administration of antibiotics. 
After exsanguinations, the lungs were dissected and removed under aseptic conditions. 
Organs used for bacteriological analysis were homogenized and cultured quantitatively 
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by serial dilutions on Mueller Hinton II agar plates. Lung tissue for histological 
examination was fixed in 10% buffered formalin and stained with hematoxylin-eosin. 
Specimens were examined under a microscope, and total abscesses were counted. The 
lung area was calculated by using cross-section paper. 
 
Enzyme-linked immunosorbent assays (ELISA) 
Concentrations of TNF-, MIP-2, and IL-1 in the lung homogenates were assayed by 
using mouse cytokine ELISA kits (R & D Systems, Minneapolis, MN, USA). 
 
Statistical analysis 
Bacteriological and cytokine data were expressed as means±SEM, and survival data 
were expressed by Kaplan-Meyer curves. Differences between groups were examined 
with the unpaired t-test. P values less than 0.05 were considered statistically significant. 
 
Results 
MIC of each antibiotic for PVL-positive S. aureus 





Bacteriological effects of antibacterial agents 
When antibiotics were administrated for 1 day, the number of bacteria in the lungs in the 
control group, VCM group, and LZD group were 6.69±0.16, 6.52±0.21, and 6.30±
0.22 log cfu/ml, respectively (No statistically significant differences) (Fig. 1, panel a).  
When antibiotics were administrated for 3 days, the number of bacteria in the 
lungs in the control group was 6.77±0.14 (log cfu/ml). In contrast, the numbers in the 
VCM and LZD groups were 5.29±0.27 and 4.25±0.33 (log cfu/ml), respectively. The 
treatment with VCM significantly decreased the number of viable bacteria as compared 
with the control group (p = 0.0004). Furthermore, LZD administration resulted in a 
significant decrease in the number of viable bacteria when compared with that in the 
control group (p < 0.0001) or VCM group (p = 0.0088) (Fig. 1, panel b). 
 
Histopathological examination 
Lung specimens from mice infected with PVL-positive S. aureus were microscopically 
examined 3 days after treatment, and lung abscesses consisting of bacterial colony with 
infiltrating acute inflammatory cells were found (Fig. 2). The control (panel a) and 
VCM (panel b) groups exhibited numerous abscesses and inflammation. In contrast, the 
LZD group (panel c) exhibited fewer abscesses and less inflammation than the control 
and VCM groups. 
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In whole lung specimens, the number of abscesses in control, VCM, and LZD 
groups were 15.6±4.25, 10.2±3.31, and 2.6±0.93, respectively (Fig. 3, panel a). The 
number of abscesses per cm2 also showed similar consequents (control, VCM, and LZD 
groups were 10.6±3.08, 5.89±1.91, and 1.58±0.53 count per cm2, respectively) (Fig. 
3, panel b). The numbers of abscesses in whole lungs and per lung area were 
significantly decreased in the LZD group, as compared with those in the control group 
(p = 0.013 and 0.011, respectively). There were no significant differences in the number 
of abscesses in whole lungs and per lung area between the control and VCM groups and 
between the VCM and LZD groups. 
 
Cytokine concentrations in lung extracts 
When antibiotics were administrated for 3 days, the concentrations of proinflammatory 
cytokines, TNF-, MIP-2, and IL-1, were significantly lower in the VCM and LZD 
groups as compared with the concentrations in the control group. In addition, all of 
these cytokine concentrations were lower in the LZD group than in the VCM group; 





The survival rate at day 7 post-inoculation was higher in the LZD group (100% 
survival) when compared with the VCM group (50%) and the control group (all dead 
within 6 days) (Fig. 5). 
 
Discussion 
The present study is the first report to demonstrate the establishment of the mouse 
model of PVL-positive S. aureus hematogenous pulmonary infection. Moreover, this 
model was used to compare the efficacy of LZD and VCM. LZD showed beneficial 
efficacy on bacteriological and histopathological examinations, cytokine levels, and 
survival rates. 
We previously reported the effect of LZD against a mouse model of 
hematogenous pulmonary infection with MRSA NUMR101, which was isolated from 
clinical samples at Nagasaki University Hospital.10 The results of that study are 
identical to those in the present study, with the exception of the cytokine analysis. The 
present cytokine analysis showed that proinflammatory cytokines, TNF-, MIP-2, and 
IL-1, were obviously decreased in the LZD group. This finding supports that LZD 
significantly reduces the number of bacteria and level of inflammation in the lungs. 
In the present study, although the MIC of LZD for PVL-positive S. aureus was 
higher than that of VCM, LZD was more effective than VCM against PVL-positive S. 
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aureus infection in vivo. There are several explanations for this discrepancy. LZD may 
inhibit PVL production, probably resulting in the reduced pathogenicity of PVL-positive 
S. aureus, because LZD markedly suppresses translation of the PVL gene,13 and a 
subinhibitory concentration of LZD (but not VCM) inhibits the PVL level in a 
concentration-dependent manner.14 Secondly, LZD inhibits other staphylococcal 
virulence factors, enterotoxin A and B,15 bifunctional autolysin, 15 and autolysin, protein 
A, 15 also indicating the reduced pathogenicity. A third reason is that the time above 
MIC of LZD was similar to that of VCM in the previous study10, implying the equal 
efficacy of antibiotics. Thus, LZD was more effective against PVL-positive S. aureus 
infection in vivo, compared with VCM. Although the sub-MIC effect of LZD against 
PVL production was not examined in the present study, it needs to be examined in the 
future. 
In conclusion, LZD clearly reduced bacterial numbers and inflammation in a 
mouse model of PVL-positive S. aureus hematogenous, and LZD improved the survival 
rate, as compared with VCM. LZD is thus considered to be clinically effective against 
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Figure 1. Effects of LZD and VCM on the number of bacteria in the lungs of mice with 
PVL-positive S. aureus hematogenous infection. Mice were treated with each agent for 
1 day (a) or 3 days (b)  
 
Figure 2. Histopathological examination of lung specimens from mice sacrificed 3 days 
after treatment for PVL-positive S. aureus. Each specimen exhibited typical features of 
bronchopneumonia with accumulation of neutrophils inside the bronchial lumen, 
infiltration of acute inflammatory cells, and exudates in the alveolar spaces 
(hematoxylin and eosin stain; original magnification, ×50). (a) control, (b) 
VCM-treated mice, (c) LZD-treated mice. Note that the severity of the inflammatory 
process is lower in LZD group as compared with the other 2 groups. 
Number of abscesses in whole lungs (d) and per lung area (e) in the PVL-positive S. 
aureus infection model. Specimens were examined under a microscope, and lung area 




Figure 3. Effects of LZD and VCM on the concentrations of cytokines and the survival 
rate of mice. Concentrations of TNF- (a), IL-1 (b), and MIP-2 (c) in the lung 
homogenates of mice infected with PVL-positive S. aureus. Mice were treated with 
each agent for 3 days after infection with PVL-positive S. aureus. These cytokine 
concentrations were assessed by ELISA. 
Effects of LZD and VCM on the survival rate of mice (d). Mice were treated with each 
agent after infection with PVL-positive S .aureus. The survival rate was determined 


















































* v.s . contor p<0.05
v.s . VCM 100mg/kg   p<0.05†
Figure 1. 

















































































control VCM 100 mg/kg LZD 100 mg/kg
0
control VCM 100 mg/kg LZD 100 mg/kg
* v.s. control        p<0.05
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Figure 3. 
